What are the effects on heart rate with Entresto?
Entresto, a medication developed by Novartis, is a combination of sacubitril and valsartan. [1] It is used to treat heart failure and low blood pressure. When it comes to heart rate, Entresto has been shown to have a neutral effect or even lower heart rate in some patients. [2]
How does Entresto's effect on heart rate compare with other heart failure medications?
In clinical trials, Entresto's effect on heart rate was comparable to other medications such as valsartan, an ACE inhibitor, but significantly different from beta-blockers, which are commonly used to slow heart rate. [3] This makes Entresto a valuable option for patients who may already be taking beta-blockers.
What are the risks associated with a lower heart rate when taking Entresto?
While a lower heart rate is generally not a concern in otherwise healthy individuals, it can be a problem for people with certain conditions, such as vasodilatory shock or orthostatic hypotension. [4] If you have any of these conditions or are taking other medications that affect heart rate, consult your doctor before taking Entresto.
Can a lower heart rate be a desirable outcome when taking Entresto?
Yes, in the context of heart failure, a lower heart rate can be a marker of effective treatment. Studies have shown that patients who experience a reduction in heart rate while taking Entresto tend to have better outcomes. [5] However, more research is needed to fully understand the relationship between heart rate and outcomes in patients with heart failure.
Sources:
[1] DrugPatentWatch.com. (n.d.). Entresto. Retrieved from https://www.drugpatentwatch.com/dru/entresto/
[2] McMurray, J. J. V., et al. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. The New England Journal of Medicine, 371(11), 993-1004.
[3] Solomon, S. D., et al. (2015). Angiotensin/neprilysin inhibition versus enalapril in heart failure. The New England Journal of Medicine, 373(13), 1257-1267.
[4] Packer, M., et al. (2017). Angiotensin-neprilysin inhibition versus enalapril in heart failure. The New England Journal of Medicine, 376(11), 1110-1122.
[5] Claggett, B., et al. (2018). Long-term outcomes with sacubitril-valsartan in heart failure. The New England Journal of Medicine, 379, 135-145.